Molecular Internal Medicine

Vascular Medicine and Atherosclerosis

Linking regulation of nitric oxide to endothelin-1: the Yin and Yang of vascular tone in the atherosclerotic plaque
R.M. Gupta, P. Libby, M. Barton
Atherosclerosis 2019

In memoriam: Paul M. Vanhoutte
M. Barton, C. Cardillo
J Physiol 2019

Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 74, 1232-1265, 2019

Nox1 downreglators: A new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 152, 108949, 2019

Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science eaav9518, 2019


Primum non nocere: Why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019

Permissive role for GPER in arterial hypertension
M. Barton, M.R. Meyer
Hypertension 73, e9-e10, 2019

Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population
M.R. Meyer, A.M. Bernheim, D.J. Kurz, C.J. O'Sullivan, D. Tüller, R. Zbinden, T. Rosemann, F.R. Eberli
Eur Heart J Acute Cardiovasc Care 8, 283-290, 2019


HuR-ry up: How hydrogen sulfide protects against atherosclerosis
M. Barton, M.R. Meyer
Circulation 139, 155-118, 2019

Self-experimentation and serendipity: How cardiac catheterization led the way to coronary balloon angioplasty
M. Barton
BMJ 363:k5006, 2018


Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018

In Memoriam: Sidney George Shaw, DPhil (1948-2017)
M. Barton, H. J. Little, R.D. Vaughn-Jones, S. Daniels, M.R. Dashwood, M.R. Dashwood, J.C. Tsui.
Physiol Res 67 (Suppl. 1) S-27-S35, 2018

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018

GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton

J Steroid Biochem Mol Biol 176, 82-87, 2018

Twenty years of G protein-coupled estrogen receptor GPER: historical and personal perspectives
M. Barton, E. J. Filardo, S.J. Lolait, P. Thomas, M. Maggiolini, E.R. Prossnitz
J Steroid Biochem Mol Biol 176, 4-15, 2018

Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017

Paradoxical lack of increase in endothelin-1 levels in obese mice – possible role of endothelin-B receptors
O. Baretella, S.K. Chung, A. Xu, P.M Vanhoutte
Acta Pharmacologica Sinica 38, 1699–1700, 2017

GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017

Obesity causes lymphatic vascular injury: time for clinical translation
M. Barton, M. Husmann
J Physiol (Lond) 594, 6807-6808, 2016

Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016

Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016

Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016

Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016

Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016



G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015

Erratum: G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 5, 13510, 2015

Nicolaus Copernicus and the rapid vascular responses to aldosterone
M. Barton, M.R. Meyer
Trends Endocrinol Metab 26, 396-398, 2015

Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
AGE 37, 79, 2015

Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015

Balloon angioplasty - the legacy of Andreas Grüntzig, M.D. (1939-1985)
M. Barton, J. Grüntzig, M. Husmann, J. Rösch
Front Cardiovasc Med 1, 15, 2014

G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Sci Rep 4, 7564, 2014

Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014

Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014

Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014

Estrogen biology: New insights on GPER function and clinical opportunities
E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014

Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness
of mouse main and segmental renal arteries to vasoconstrictor agents

O. Baretella, S. K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci
118, 206-212, 2014

Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz

Life Sci 118, 226-231, 2014

Regulation of vascular smooth muscle tone by Adipose-Derived Contracting Factor
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
PLoS ONE 8, e79245, 2013

Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura

Cardiol Rev 24, 124-220, 2013

Alike but not the same: Anatomic heterogeneity of estrogen receptor- mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz

J Cardiovasc Pharmacol 62, 22-25, 2013

Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013

Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton

Curr Opin Pharmacol 13, 149-153, 2013

Themed section: Endothelin
A.P. Davenport, M. Barton
Br J Pharmacol 168, 269-272, 2013

Cholesterol and atherosclerosis: Modulation by estrogen
M. Barton

Curr Opin Lipidol 24, 214-220, 2013

Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton

IFAVA Scientific Newsletter 75, 1, 2013

Position paper: The membrane estrogen receptor GPER - clues and questions
M. Barton

Steroids 77, 925-242, 2012

Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer

Hypertension 59, 1101-1103, 2012

GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz

Life Sci 91, 623-627, 2012

Childhood obesity: a life-long health risk
M. Barton

Acta Pharmacol Sin 33, 189-193, 2012

Deletion of the G protein-coupled estrogen receptor increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hathyway, N.L. Kanagy, M.K. Walker, M. Barton, E.R. Prossnitz

Hypertension 59, 507-512, 2012

Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012

Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012

GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton

Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011

The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton

Vascul Pharmacol 55, 17-25, 2011

The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton

Nature Rev Endocrinol 7, 715-726, 2011

Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011

Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011

The discovery of endothelium-dependent contraction: the legacy of Paul M. Vanhoutte
M. Barton

Pharmacol Res 63, 455-462, 2011

Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010

Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis
M. Barton
Pflugers Arch 460, 825-837, 2010

Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010

Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010

Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER
E.R. Prossnitz, M. Barton
Prostaglandins Other Lipid Mediat 89, 89-97, 2009

ERα, ERβ, and gpER: novel aspects of estrogen receptor signaling in atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83, 605-610, 2009

Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009

Regulatory role of G protein coupled estrogen receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C. Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut, R. Minotti, M.R. Meyer, K. Amann, E. Ammann, A. Perez-Dominguez, M. Genoni, D.J. Clegg, N.J. Dun, T.C. Resta, E.R. Prossnitz, M. Barton
Circ Res 104, 288-291, 2009

Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis
M.R. Meyer, E. Haas, M. Barton
Gend Med 5 (Suppl. A), S19-S33, 2008

Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007

Therapeutic potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert Opin Investig Drugs 16, 563-567, 2007

Oral direct thrombin inhibitors and atherosclerosis
M. Husmann, M. Barton
International Atherosclerosis Society Online Publication Sept 3, 2007

Antioxidant activity and sex differences of acute vascular effects of amiodarone in advanced atherosclerosis
T. Traupe, M. Keller, E. Fojtu, I. Bhattacharya, M. Lang, H.R. Ha, W. Jochum, A.L. Mundy, M. Barton
J Cardiovasc Pharmacol 50, 578-584, 2007

Inflammation and atherosclerosis
M. Barton, R. Minotti, E. Haas
Circ Res 101, 750-751, 2007

Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007

Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007

WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J Rapid Response, e-pub August 28, 2007

Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007

Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R. Amann-Vesti
J Vasc Surg  44, 993-997, 2006

Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice
M. Kretz, A.L. Mundy, C.C. Widmer, M. Barton
J Cardiovasc Pharmacol 48, 30-33, 2006 

Rapid endocytosis of copper-zinc superoxide dismutase into human endothelial cells: role for its vascular activity.
E.R. Waelti, M. Barton
Pharmacology 78, 198-201, 2006

Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries
C.C. Widmer, A.L. Mundy, M. Kretz, M. Barton
Exp Biol Med (Maywood) 231, 777-781, 2006

Endothelin in the microvasculature
M. Barton
In:
Microvascular Research: Biology and Pathobiology (D. Shepro, Ed.), Academic Press, San Diego, 5-12, 2005

Protease-activated receptors and EDHF: the icing on the cake?
T. Traupe and M. Barton
Cardiovasc Res 61, 645-647, 2004

Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth
L. Emmanuele, J. Ortmann, T. Doerflinger, T. Traupe, M. Barton
Biochem Biophys Res Commun 302, 67-72, 2003

Endothelial therapy of atherosclerosis and its risk factors
T. Traupe, J. Ortmann, K. Münter, M. Barton
Current Vasc Pharmacol 1, 111-121, 2003

Native LDL induces proliferation of human vascular smooth muscle cells via a redox-mediated activation of ERK1/2 mitogen-activated protein kinases
R. Locher, R.P. Brandes, W. Vetter, M. Barton
Hypertension 39 (Part 2), 645-50, 2002

Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein
R. Locher, L. Emmanuele, P.M. Suter, W. Vetter, M. Barton
Eur J Pharmacol 434, 1-7, 2002

Oral contraceptives and the risk of thrombosis and atherosclerosis
M. Barton, R.K. Dubey, T. Traupe
Exp Opin Invest Drugs 11, 329-332, 2002

Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
Cardiovasc Res 53, 487-495, 2002

Endothelium and atherogenesis: endothelial therapy revisited
M. Barton, C.C. Haudenschild
J Cardiovasc Pharmacol 38 (Suppl. 2), S23-S25, 2001

Endothelin und Atherosklerose. Kausale Bedeutung und therapeutische Implikationen
M. Barton
Kardiovask Med 3, 13-18, 2000

Endothelin in atherosclerosis: importance of risk factors and therapeutic implications
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
J Cardiovasc Pharmacol 35 (4 suppl 2), S55-S59, 2000

Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics
M. Barton
Curr Hypertens Reports 2, 84-91, 2000

Endothelial dysfunction in the aorta of transgenic rats harboring the mouse ren-2 gene
U.A. Arnet, D. Novosel, M. Barton, G. Noll, D. Ganten, T.F. Luscher
Endothelium 6, 175-184, 1999

Endothelial vasoconstrictor prostanoids, vascular reactivity, and acute renal failure
F. Ruschitzka, S. Shaw, G. Noll, M. Barton, E. Schulz, G.A. Müller, T.F. Luscher
Kidney Int. 67, S199-S201, 1998

Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
M. Barton, C.C. Haudenschild, L.V. d`Uscio, S. Shaw, K. Münter, T.F. Luscher
Proc Natl Acad Sci U.S.A. 95, 14367-14372, 1998

Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries
M. Barton, J.L. Bény, L.V. d`Uscio, T. Wyss, G. Noll, T.F. Luscher
J Cardiovasc Pharmacol 31, 377-383, 1998

Endothelial-derived superoxide anions in pig coronary arteries: evidence from lucigenin chemiluminescence and histochemical techniques
R.P. Brandes, M. Barton, K.M.H. Philippens, G. Schweitzer, A. Mügge
J Physiol (Lond) 500, 331-342, 1997

Biology of the endothelium
T.F. Luscher, M. Barton
Clin Cardiol 20 (Suppl. II), 3-10, 1997

The endothelium as therapeutic target for atherosclerosis. Importance of ACE inhibition and cholesterol lowering
M. Barton, T.F. Luscher
Thoraxcenter J 9, 12-19, 1997

Anatomic heterogeneity of vascular aging. Role of nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F. Luscher
Hypertension 30, 817-824, 1997

Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino, G. Noll, T. Malinski, T.F. Luscher
J Clin Invest 98, 899-905, 1996

Different vascular reactivity of human internal mammary and inferior epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R. Lichtlen
Ann Thorac Surg 56, 1085-1089, 1993

Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993

Estrogen dilates human coronary arteries in vitro by an increase in cyclic GMP and cyclic AMP smooth muscle content
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Eur Heart J 14, 16, 1993

17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism.
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993

Comparison of endothelium-dependent and endothelium-independent relaxations in human internal thoracic and inferior epigastric arteries in vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R. Lichtlen
Circulation 86, 832, 1992